What is Pomalyst?
Pomalyst® is an oral immunomodulatory agent (IMiD®) that is similar to Revlimid® (lenalidomide, Celgene) and Thalomid® (thalidomide, Celgene) but is more potent.
Pomalyst is also called pomalidomide and is also made by Celgene. In the United States, Pomalyst is approved for the use in patients with myeloma who have received at least two prior therapies, including Velcade® (bortezomib, Takeda Oncology) or another proteasome inhibitor and Revlimid and who have demonstrated disease progression on or within 60 days of completion of the last therapy.
The Multiple Myeloma Research Consortium (MMRC) played a substantial role in the development of this drug as a partner with Celgene in the early clinical trials establishing its efficacy and continues to sponsor trials evaluating Pomalyst in combination with various myeloma drugs.